Multiple Myeloma Sequencing Evolves With CAR T, MRD Insights: Sylvester Homsy, MD

Why It Matters

Earlier use of CAR‑T and bispecifics promises deeper remissions, while MRD‑driven decisions could personalize care, but systemic hurdles risk uneven patient outcomes.

Key Takeaways

• CAR‑T and bispecifics moving to earlier multiple myeloma lines
• MRD testing reshapes response assessment across treatment phases
• Lack of standardization hampers MRD adoption in community settings
• Access and infrastructure challenges limit early use of novel therapies
• Clinicians must balance traditional combos with high‑efficacy novel agents

Pulse Analysis

The rapid rollout of CAR‑T cell therapies and bispecific antibodies is redefining multiple myeloma care. Trials have shown response rates exceeding 80 percent and progression‑free survival gains that dwarf historic regimens, encouraging oncologists to contemplate these modalities in first‑line or early‑line settings. This shift challenges entrenched sequencing algorithms that traditionally relied on proteasome inhibitors, immunomodulatory drugs, and steroid combos, forcing a reevaluation of risk‑benefit calculations for each patient.

Measurable residual disease (MRD) testing has emerged as a pivotal biomarker, moving beyond a research endpoint to a clinical decision tool. Sensitive assays can detect one cancer cell among a million, allowing physicians to gauge depth of response after induction, during consolidation, and throughout maintenance. Early MRD negativity correlates with longer overall survival, prompting many centers to integrate testing into treatment pathways. Yet, without uniform standards for assay platforms, timing, and reporting, MRD adoption remains fragmented, especially outside academic trials.

Despite the promise, practical barriers threaten equitable access to these innovations. CAR‑T manufacturing requires specialized facilities, and reimbursement frameworks are still evolving, creating geographic and socioeconomic gaps. Bispecific antibodies, while off‑the‑shelf, demand vigilant monitoring for cytokine release and neurotoxicity, necessitating trained staff and infrastructure. Policymakers, payers, and health systems must align on coverage policies, invest in training, and develop consensus guidelines to ensure that the therapeutic gains of early‑line CAR‑T, bispecifics, and MRD‑guided strategies reach all patients.